Phase 2 N=30 CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=80 Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma
Hodgkin Disease
Primary: Objective Overall Response Rate (ORR) in Relapsed or Refractory cHL. — 21.0; 28.6 percentage of participants
N/A N=1,598 B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes
Classical Hodgkin Lymphoma · Relapsed or Refractory Classical Hodgkin Lymphoma
Primary: Group 2, RRHL: Progression Free Survival (PFS) — 13.17 months
Phase 2 N=57 Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) Based on the Assessments by Investigator — 8.8; 36.8; 45.6 percentage of participants
Phase 2 N=96 Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
Relapsed/Refractory Classical Hodgkin's Lymphoma
Primary: Objective Response Rate (ORR) Assessed According to the Revised International Working Group Response Criteria for Malignant Lymphoma in 2007(IWG 2007) by the Independent…
Phase 2 N=42 Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Lymphoma
Primary: Progression-free Survival — 18 participants
Phase 2 N=118 Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
Lymphoma
Primary: Objective Response — 3; 6; 3; 2 participants
Phase 2 N=129 Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
Classical Hodgkin's Lymphoma
Primary: Objective Response Rate (ORR) as Assessed by the Investigator Based on Cheson Response Criteria — 5; 30; 71; 14 Participants
Phase 2 N=17 LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Phase 2 N=24 Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma
Hodgkin's Lymphoma
Primary: Objective Response Rate (ORR) — 25.00; 37.50; 75.00; 62.50 percentage of patients
Phase 2 N=34 Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Complete Response Rate — 34 Participants
Phase 2 N=296 Therapy for Pediatric Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Event-free Survival Probability by Risk Group — 0.886; 0.844; 0.667; 0.793 probability of 5 yr. event free survival
Phase 2 N=98 S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
Lymphoma
Primary: 2-year Progression-free Survival — 59 percentage of participants
Phase 2 N=39 Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Complete Response (CR) Rate — 0; 36 percent of participants
Phase 2 N=75 PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma
Hodgkin Lymphoma, Adult
Primary: ORR Assess by IRC — 76.0 percentage
Phase 2 N=36 Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma
Hodgkin's Disease · Lymphoma
Primary: Determine the Overall Response Rate (RR) to Bendamustine HCL in Patients With Relapsed and Primary Refractory HL. — 56 percentage of evaluable participants
Phase 2 N=25 Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Overall Response Rate — 20.0 percentage of participants
Phase 2 N=45 Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma · Refractory Hodgkin Lymphoma
Primary: Maximum Tolerated Dose of Brentuximab Vedotin That Can be Combined With Ifosfamide, Carboplatin, and Etoposide Chemotherapy — 1.5 mg/kg
Phase 2 N=30 Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma
Lymphoma
Primary: Number of Participants With Grade 3-5 Adverse Events — 6 Participants
Phase 2 N=23 Autologous and Allogeneic Transplant for Relapsed Lymphoma
Non-Hodgkin's Lymphoma · Hodgkins Disease
Primary: Total Number of Subjects With a Complete Response (CR) Following Myeloablative Conditioning (MAC) and Autologous Stem Cell Transplantation (AutoSCT) — 4; 12 Participants
Phase 4 N=60 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 50 percentage of participants
Phase 2 N=39 Rituximab in Treating Patients With Hodgkin's Lymphoma
Lymphoma · Hodgkin Lymphoma (Category) · Nodular Lymphocyte Predominant Hodgkin Lymphoma
Primary: Progression-free Survival (PFS) — 18 participants
Phase 2 N=37 Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk
Hodgkin Lymphoma
Primary: Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability of Nivolumab as Maintenance Therapy — 33 Participants
Phase 2 N=50 Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma
Lymphoma
Primary: Effect of Rituximab on EBV(+) Tumors — 0 relapses
N/A N=41 Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
Hodgkin Lymphoma, Adult
Primary: Percentage of Patients With Positron Emission Tomography (PET) Negative Disease — 37 Participants
Phase 1 N=133 Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma
Hodgkin Lymphoma · Non-Hodgkin Lymphoma
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 2 N=50 Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Hodgkin Lymphoma · Diffuse Large B-Cell Lymphoma
Primary: Progression Free Survival (PFS) — 6.6 months
Phase 2 N=96 Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Non-Hodgkin's Lymphoma
Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients
Phase 2 N=80 Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
Hodgkin's Lymphoma
Primary: 3-year Event-Free Survival Probability — 0.887 probability — p=0.9970
Phase 2 N=82 Rituximab and ABVD for Hodgkin's Patients
Lymphoma
Primary: 5-year Failure-free Survival Rate for Participants With Hodgkin's Disease Given Rituximab With ABVD — 83 percentage of participants